Literature DB >> 23122806

Validation and proposals for a refinement of the WHO 2008 classification of myelodysplastic syndromes without excess of blasts.

Anna Maassen1, Corinna Strupp, Aristoteles Giagounidis, Andrea Kuendgen, Kathrin Nachtkamp, Barbara Hildebrandt, Norbert Gattermann, Carlo Aul, Rainer Haas, Ulrich Germing.   

Abstract

In 2008, the WHO proposed changes in the classification of MDS regarding RCUD and MDS unclassifiable. We validated these proposals by using 2032 patients of the Düsseldorf MDS Registry. 10% of the patients had RCUD and 6% MDS-U. Among patients with RCUD, only 9% had RN and 6% had RT. There was no correlation between dysplastic cell line and type of cytopenia. There was no difference in prognosis between RCMD and MDS-U and between RA, RT, and RN. The separation of RA, RN, and RT is not justified suggesting a consolidation as RCUD. MDS-U should be integrated into RCMD.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23122806     DOI: 10.1016/j.leukres.2012.09.021

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  7 in total

Review 1.  [Myelodysplastic syndromes. Epidemiology, molecular and morphological characteristics and risk stratification].

Authors:  A H Schmitt-Graeff; M J Müller; P Fisch
Journal:  Pathologe       Date:  2013-02       Impact factor: 1.011

2.  Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group.

Authors:  Theresia M Westers; Eline M P Cremers; Uta Oelschlaegel; Ulrika Johansson; Peter Bettelheim; Sergio Matarraz; Alberto Orfao; Bijan Moshaver; Lisa Eidenschink Brodersen; Michael R Loken; Denise A Wells; Dolores Subirá; Matthew Cullen; Jeroen G Te Marvelde; Vincent H J van der Velden; Frank W M B Preijers; Sung-Chao Chu; Jean Feuillard; Estelle Guérin; Katherina Psarra; Anna Porwit; Leonie Saft; Robin Ireland; Timothy Milne; Marie C Béné; Birgit I Witte; Matteo G Della Porta; Wolfgang Kern; Arjan A van de Loosdrecht
Journal:  Haematologica       Date:  2016-10-06       Impact factor: 9.941

3.  Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes.

Authors:  Eline M P Cremers; Theresia M Westers; Canan Alhan; Claudia Cali; Heleen A Visser-Wisselaar; Dana A Chitu; Vincent H J van der Velden; Jeroen G Te Marvelde; Saskia K Klein; Petra Muus; Edo Vellenga; Georgina E de Greef; Marie-Cecile C J C Legdeur; Pierre W Wijermans; Marian J P L Stevens-Kroef; Pedro da Silva-Coelho; Joop H Jansen; Gert J Ossenkoppele; Arjan A van de Loosdrecht
Journal:  Haematologica       Date:  2016-09-22       Impact factor: 9.941

4.  Prognostic mutations in persons with isolated neutropenia myelodysplastic syndrome.

Authors:  Zhongxun Shi; Tiejun Qin; Zefeng Xu; Bing Li; Huijun Huang; Hongli Zhang; Liwei Fang; Lijuan Pan; Naibo Hu; Shiqiang Qu; Gang Huang; Robert Peter Gale; Zhijian Xiao
Journal:  Leuk Lymphoma       Date:  2019-05-06

Review 5.  Refractory thrombocytopenia and neutropenia: a diagnostic challenge.

Authors:  Emmanuel Gyan; François Dreyfus; Pierre Fenaux
Journal:  Mediterr J Hematol Infect Dis       Date:  2015-02-18       Impact factor: 2.576

Review 6.  Acquired myelodysplasia or myelodysplastic syndrome: clearing the fog.

Authors:  Ethan A Natelson; David Pyatt
Journal:  Adv Hematol       Date:  2013-10-07

7.  Genomic alterations in patients with somatic loss of the Y chromosome as the sole cytogenetic finding in bone marrow cells.

Authors:  Madhu M Ouseph; Robert P Hasserjian; Paola Dal Cin; Scott B Lovitch; David P Steensma; Valentina Nardi; Olga K Weinberg
Journal:  Haematologica       Date:  2021-02-01       Impact factor: 9.941

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.